Release of Omriclo 150mg dosage… Expansion of lineup next year Enhancing brand awareness in the Brazilian market → Increased prescriptions Strengthening influence in the Latin American market from Brazil next year
Celltrion's Third Plant
Celltrion announced on the 27th that it is launching the chronic idiopathic urticaria treatment 'Omriclo' (ingredient name: omalizumab) in Brazil, the largest pharmaceutical market in Latin America, and is officially beginning its market penetration.
Omriclo is the first-mover omalizumab biosimilar product to be launched in the Brazilian market. The company has initially released the 150mg dosage and plans to add the 75mg product early next year.
Before the launch of Omriclo, Celltrion's Brazilian subsidiary actively promoted the product's competitiveness and stable supply capabilities to local pharmaceutical buyers and medical institutions. Given that Brazilian medical professionals have been prescribing Celltrion products for many years, a swift market entry is anticipated.
Marketing activities targeting medical professionals have also been actively conducted. On the 13th (local time), the company participated in the Brazilian Society of Allergy and Immunology, introducing Omriclo's clinical data and treatment convenience to local medical professionals.
Celltrion Omriclo
The growth of Celltrion's major products in Brazil is forming a virtuous cycle foundation, leading to enhanced brand recognition and increased trust in new products. As of the second quarter of this year, the blood cancer treatment 'Truxima' (rituximab) recorded approximately 80% market share in Brazil's private sector. The autoimmune disease treatment 'Remsima' (infliximab) also achieved significant results with a market share in the 60% range in the same sector.
Based on the performance of existing products, Celltrion plans to ensure the successful market entry of subsequent products like Omriclo. The company also aims to expand its product portfolio across the entire Latin American market and strengthen its regional presence.
Kang Kyung-doo, Head of Celltrion's Latin America Region, stated, "We plan to rapidly expand prescriptions by leveraging the early market entry advantage as a first-mover in Brazil," adding, "Starting from Brazil, we will actively expand the countries selling Omriclo within the Latin American region from next year and further solidify our regional presence."
Meanwhile, Omriclo, developed by Celltrion, is used to treat chronic idiopathic urticaria and asthma. The original drug, Xolair, achieved blockbuster status with global sales of approximately KRW 6.4992 trillion last year.
Kim Min-beom
AI-translated with ChatGPT. Provided as is; original Korean text prevails.
ⓒ dongA.com. All rights reserved. Reproduction, redistribution, or use for AI training prohibited.
